Vor Biopharma Inc. (VOR) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Median CD33 Editing Efficiency | 90.00 percent | FY2024-Q4 |
| Number of Patients Treated with Trem-cel | 25.00 | FY2024-Q4 |
| Primary Neutrophil Engraftment Rate | 100.00 percent | FY2024-Q4 |
Back to VOR overview · VOR earnings · VOR holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.